Jan. 8 at 12:19 AM
$CUBT
Paul M MichaelsPaul M Michaels
Executive Chairman, co-CEO & President Curative Biotechnology, Inc.
As we step into the New Year and look ahead to a productive 2026, Curative Biotech remains focused on thoughtful growth, seeking programs that align with our model. We deliberately pursue indications with significant unmet medical need, guided by a patient-first mindset at every stage of development. Whether human or canine, our objective is to advance programs to meaningful value-creating inflection points that truly matter for patients.
In some cases, the final stages of development and commercialization are best executed by larger partners with the scale, infrastructure, and global expertise to bring therapies to patients efficiently and responsibly. In those hands, programs are well positioned to succeed. Our company is built on reaching those critical inflection points we can monetize—while ensuring each program ultimately resides with the partner best equipped.